On October 22, 2025, Econic Partners’ client Avadel Pharmaceuticals announced a global settlement of all litigation with Jazz Pharmaceuticals, including outstanding intellectual property and antitrust claims.
Econic Partners Founding Partner Jon Orszag was retained by Avadel to submit expert testimony on Avadel’s antitrust counterclaims against Jazz. Mr. Orszag submitted multiple expert reports opining on market definition, competitive effects, and damages.
Under the terms of the settlement agreement, Jazz agreed to pay Avadel $90 million and to waive royalties on past sales of LUMRYZ, and granted LUMRYZ a perpetual worldwide license to any patents asserted against LUMRYZ. In addition, Jazz agreed not to challenge the approvability of LUMRYZ for any and all present and future indications (e.g., idiopathic hypersomnia), and Avadel agreed to pay Jazz certain royalties through February 2036.
Mr. Orszag was supported by Dr. Bret Dickey, Taylor Hines, Dr. Mark Rodini, Avika Jindel, and Aaron Jue-Sans at Econic Partners, as well as Tully Lillis and Tess Monahan at Compass Lexecon. The team worked closely with counsel, including Alan Devlin, Ken Schuler, Anna Rathbun, and Chris Brown of Latham & Watkins and Alexander Okuliar, Daralyn Durie, Henry Huttinger, and Helen He of Morrison Foerster.
